Periodontitis Treatment and Heart Failure
Launched by UNIVERSITY OF TAUBATE · Jun 23, 2025
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of \> 40 million individuals globally; while periodontitis affects 50% of people in general, and its most severe form affects approximately 11% of the population. The primary objective of this study is to evaluate the effect of periodontal therapy on blood levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 3 and at 6 months. Secondary aims are the relation between biomarker blood levels and a) functional classes and b) its salivary levels. Antibodies against P. gingivalis besides species...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • minimum of 35 years of age;
- • possibility and availability for medical and dental examinations;
- • specifically for HF groups: HF having as primary causes ischemic problems, myocardial infarction, hypertension and valvulopathies will be selected
- • HF with intermediate or reduced ejection fraction under one of the three following pharmacological therapeutic regimens: a) Angiotensin Converting Enzyme Inhibitors, as the first option, or b) Angiotensin II Receptor Blockers and b) Angiotensin II Receptor Blockers and c) Angiotensin/neprilysin receptor inhibitors.
- Exclusion Criteria:
- • pregnant or lactating women;
- • individuals with stage D of HF using vasoactive drugs or circulatory devices;
- • HF individuals with preserved ejection fraction;
- • participants who do not meet the criteria for periodontal disease;
- • participants who are unable to comply with the study protocol;
- • diabetes, obesity, chronic kidney disease and other non-ischemic causes of HF;
- • familial and congenital heart alterations and myocarditis
- • rheumatological and autoimmune diseases;
- • drugs and cardiotoxic substances such as cocaine and oncological chemotherapy;
- • Specifically for the negative control group a progression of periodontitis revealed by 0.3mm additional clinical attachment loss within 6 months of follow-up.
About University Of Taubate
The University of Taubaté, a prominent educational and research institution in Brazil, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment where cutting-edge research and ethical standards converge to enhance patient care and public health outcomes. Its commitment to excellence is reflected in its rigorous methodologies, robust participant engagement, and a focus on translating research findings into meaningful clinical applications. Through its clinical trial initiatives, the University of Taubaté aims to contribute significantly to the global body of medical knowledge and improve healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taubaté, , Brazil
Patients applied
Trial Officials
Jose R Cortelli, Doctorate
Principal Investigator
University of Taubate
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported